BREATH Trial Reduced Distress in Early Breast Cancer Survivors
the Cancer Therapy Advisor take:
The Breast Cancer E-Heath (BREATH) trial combined with care as usual (CAU) was associated with significantly less distress in patients compared to CAU alone, according to an article published online in Journal of Clinical Oncology.
The BREATH trial is a Web-based self-management intervention available to breast cancer survivors (BCSs) that provides support for the psychological adjustment after primary treatment. BREATH consists of 16 automated weekly modules covering issues survivors may face early on.
In this study, BCSs were assigned to receive CAU + BREATH (n = 70) or CAU alone (n = 80) 2 to 4 months post-treatment.
Results showed participants in the CAU + BREATH cohort experienced significantly less distress than those in the CAU alone group (−7.79; 95% CI: −14.31, −1.27; P=0.02), with a small-to-medium effect size (d=0.33). However, empowerment was not determined to be affected (−1.71; 95% CI: 5.20, −1.79; P=0.34).
Furthermore, it was observed that in low-distress BCSs, a higher number of individuals in the CAU + BREATH cohort (39 of 70 [56%]; 95% CI: 44.1, 66.8) displayed clinically significant improvement (P=0.03), compared with those in the CAU alone cohort (32 of 80 [40%]; 95% CI: 30.0, 51.0).
The authors noted that the reduced distress observed in patients primarily was not sustained during follow-up.
Breast Cancer E-Heath (BREATH) trial combined with care as usual associated with significantly less distress compared to CAU alone.
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Breast Implant-Associated Anaplastic Large Cell Lymphoma — In the Clinic
- Immune Checkpoint Inhibitors for NSCLC: Current and Future Approaches
- Can A Consortium of Hospitals Help To Reduce Drug Prices?
- Clostridium Difficile Infection in Patients With Cancer — In the Clinic
- 5α-Reductase Inhibitors Do Not Increase Risk of High-Grade Prostate Cancer
- FDA Approves Front-Line Brentuximab Vedotin Plus Chemotherapy for Hodgkin Lymphoma
- NSCLC: Pretreatment Weight Loss May Be Linked to Socioeconomic Status
- Targeted and Immunotherapies for Metastatic Renal Cell Carcinoma
- Atezolizumab, Carboplatin, Nab-Paclitaxel Combination Prolongs PFS in NSCLC
- Model May Identify Patients With Gastric Cancer Likely To Benefit From Chemotherapy